Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis

Journal of Cutaneous Pathology

Volumn 28, Issue 9, 2001, Pages 470-475

  Nguyen Vu, Phuong Anh ^a   Fackler, Ingrid ^a   Rust, Adelheid ^b   Declue, Jeffrey E ^c   Sander, Christian A ^a   Volkenandt, Matthias ^a   Flaig, Michael ^a   Yeung, Raymond S ^d   Wienecke, Ralf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; GENE PRODUCT; GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TUBERIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DISEASE ASSOCIATION; EMBRYO; ENDOTHELIUM CELL; HEMANGIOFIBROMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; RAT; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

ANGIOFIBROMA; ANIMALS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, MUTANT STRAINS; REPRESSOR PROTEINS; RIBONUCLEASE, PANCREATIC; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASCULAR NEOPLASMS;

EID: 0034832919     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2001.028009470.x     Document Type: Article

References (29)

1. Prevalence of tuberous sclerosis estimated by capture-recapture analysis
2. Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria
3. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features
4. Variability of expression in tuberous sclerosis
5. Dermatologic manifestations
6. Adenoma sebaceum of Pringle: A clinicopathologic review
7. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34
8. Identification and characterization of the tuberous sclerosis gene on chromosome 16
9. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: No evidence for genotype-phenotype correlation
10. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles
11. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products
12. Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus
13. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues
14. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity
15. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase-activating protein (GAP) in modulating endocytosis
16. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral
17. Beta-adrenergic-induced cytosolic redistribution of Rap1 in rat parotid acini: Role in secretion
18. Regulation of membrane transport through the endocytic pathway by rabGTPases
19. Predisposition to renal carcinoma in the Eker rat is determined by germ- line mutation of the tuberous sclerosis 2 (TSC2) gene
20. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic heman-gioblastomas
21. Analysis of vascularity of human neurofibromas
22. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monodonal anti-alkaline phosphatase (APAAP complexes)
23. Loss of heterozygosity in tuberous sclerosis hamartomas
24. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions
25. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors
26. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
27. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
28. Lens-specific expression of PDGF-A in transgenic mice results in retinal astrocytic hamartomas
29. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity